Skip to main content

Table 1 Select Characteristics of New Users of Palbociclib Identified in the HIRD

From: Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study

Characteristicsa

All new users of palbociclib

New users of palbociclib-fulvestrant

New users of palbociclib-letrozole

All other new users of palbociclib

N/Mean

%/SD

N/Mean

%/SD

N/Mean

%/SD

N/Mean

%/SD

Overall

2445

100%

566

100%

1159

100%

720

100%

Total duration of follow-up of cohort (in years)

1540

324

812

404

Duration of follow-up (in years)

0.63

0.53

0.57

0.43

0.70

0.58

0.56

0.50

Age at index date (in years)

59.79

11.62

59.47

11.38

59.21

11.27

60.95

12.29

Sex

 Male

53

2.17

< 10

n/a

14

1.21

30

4.17

 Female

2392

97.83

557

98.41

1145

98.79

690

95.83

Calendar year of index date

 2015

791

32.35

99

17.49

456

39.34

236

32.78

 2016

942

38.53

269

47.53

406

35.03

267

37.08

 2017

712

29.12

198

34.98

297

25.63

217

30.14

Geographic region of residence

 Midwest

400

16.36

95

16.78

185

15.96

120

16.67

 South

581

23.76

159

28.09

288

24.85

134

18.61

 Northeast

696

28.47

166

29.33

340

29.34

190

26.39

 West

768

31.41

146

25.80

346

29.85

276

38.33

Secondary malignancy to any site (metastasis)

2137

87.40

496

87.63

1044

90.08

597

82.92

Secondary malignancy to Lymph nodes of head, face, and neck metastasis

690

28.22

154

27.20

356

30.72

180

25.00

Secondary malignancy to Respiratory and digestive system metastasis (includes liver metastasis)

1058

43.27

257

45.41

490

42.28

311

43.19

Secondary malignancy to Metastasis to other specified sites

2017

82.49

463

81.80

978

84.38

576

80.00

Deyo-Charlson comorbidity index (DCI)

8.39

1.90

8.52

1.76

8.48

1.70

8.13

2.25

Advanced stage ER+/HER2- breast cancer

2285

93.46

548

96.82

1083

93.44

654

90.83

Radiation therapy

483

19.75

112

19.79

233

20.10

138

19.17

Chemotherapy

472

19.30

100

17.67

218

18.81

154

21.39

CT related imaging

602

24.62

139

24.56

333

28.73

130

18.06

Number of outpatient visits

39.67

25.20

38.58

23.63

39.51

23.78

40.79

28.42

Aromatase inhibitor

1527

62.45

326

57.60

815

70.32

386

53.61

HER2+ therapy

72

2.94

15

2.65

35

3.02

22

3.06

Tamoxifen

552

22.58

140

24.73

270

23.30

142

19.72

Fulvestrant

621

25.40

238

42.05

112

9.66

271

37.64

Denosumab or pamidronate

836

34.19

206

36.40

359

30.97

271

37.64

Everolimus

150

6.13

40

7.07

52

4.49

58

8.06

Antihypertensives

653

26.71

173

30.57

293

25.28

187

25.97

Corticosteroids

606

24.79

148

26.15

308

26.57

150

20.83

Lipid lowering agent

528

21.60

132

23.32

251

21.66

145

20.14

Pathologic fracture

211

8.63

46

8.13

110

9.49

55

7.64

Pure hypercholesterolemia

215

8.79

48

8.48

105

9.06

62

8.61

  1. Abbreviations: HIRD HealthCore Integrated Research Database, N number, SD standard deviation, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, CT computed tomography
  2. aAll characteristics are measured as presence within six months prior to palbociclib initiation, unless otherwise specified